BIOMARKER:

ROS1 fusion

Entrez ID:

Related biomarkers:

‹

›

ROS1 fusion ROS1 fusion	Non Small Cell Lung Cancer NSCLC	ROS1 fusion ROS1 fusion	Non Small Cell Lung Cancer NSCLC	entrectinib Sensitive: A1 - Approval	entrectinib Sensitive: A1 - Approval
ROS1 fusion ROS1 fusion	Non Small Cell Lung Cancer NSCLC	ROS1 fusion ROS1 fusion	Non Small Cell Lung Cancer NSCLC	crizotinib Sensitive: A2 - Guideline	crizotinib Sensitive: A2 - Guideline
ROS1 fusion ROS1 fusion	Melanoma Melanoma	ROS1 fusion ROS1 fusion	Melanoma Melanoma	entrectinib Sensitive: A2 - Guideline	entrectinib Sensitive: A2 - Guideline
ROS1 fusion ROS1 fusion	Melanoma Melanoma	ROS1 fusion ROS1 fusion	Melanoma Melanoma	crizotinib Sensitive: A2 - Guideline	crizotinib Sensitive: A2 - Guideline
ROS1 fusion ROS1 fusion	Solid Tumor Solid Tumor	ROS1 fusion ROS1 fusion	Solid Tumor Solid Tumor	entrectinib Sensitive: C1 - Off-label	entrectinib Sensitive: C1 - Off-label
ROS1 fusion ROS1 fusion	Non Small Cell Lung Cancer NSCLC	ROS1 fusion ROS1 fusion	Non Small Cell Lung Cancer NSCLC	TPX-0005 Sensitive: C2 – Inclusion Criteria	TPX-0005 Sensitive: C2 – Inclusion Criteria
ROS1 fusion ROS1 fusion	Non Small Cell Lung Cancer NSCLC	ROS1 fusion ROS1 fusion	Non Small Cell Lung Cancer NSCLC	AB-106 Sensitive: C2 – Inclusion Criteria	AB-106 Sensitive: C2 – Inclusion Criteria
ROS1 fusion ROS1 fusion	Non Small Cell Lung Cancer NSCLC	ROS1 fusion ROS1 fusion	Non Small Cell Lung Cancer NSCLC	ensartinib Sensitive: C3 – Early Trials	ensartinib Sensitive: C3 – Early Trials
ROS1 fusion ROS1 fusion	Non Small Cell Lung Cancer NSCLC	ROS1 fusion ROS1 fusion	Non Small Cell Lung Cancer NSCLC	durvalumab Resistant: C3 – Early Trials	durvalumab Resistant: C3 – Early Trials
ROS1 fusion ROS1 fusion	Non Small Cell Lung Cancer NSCLC	ROS1 fusion ROS1 fusion	Non Small Cell Lung Cancer NSCLC	bevacizumab + crizotinib Sensitive: C4 – Case Studies	bevacizumab + crizotinib Sensitive: C4 – Case Studies
ROS1 fusion ROS1 fusion	Glioblastoma GBM	ROS1 fusion ROS1 fusion	Glioblastoma GBM	lorlatinib Sensitive: D – Preclinical	lorlatinib Sensitive: D – Preclinical
ROS1 fusion ROS1 fusion	Solid Tumor Solid Tumor	ROS1 fusion ROS1 fusion	Solid Tumor Solid Tumor	SIM1803-1A Sensitive: D – Preclinical	SIM1803-1A Sensitive: D – Preclinical